Drug intelligence / Profile preview

Xenadrine EFX

Development stage
Unknown
Lead developer
Nutraquest
Modality
Small Molecules
Administration
Oral
01

Overview

Xenadrine EFX is a multi-ingredient dietary supplement marketed for weight loss and energy enhancement. It was developed as an "ephedra-free" (EFX) alternative following the FDA ban on ephedrine alkaloids in dietary supplements. The formulation typically contains a blend of stimulants, including caffeine, guarana extract, and bitter orange (*Citrus aurantium*) extract standardized for synephrine. Synephrine acts as a sympathomimetic agent, primarily targeting alpha-adrenergic receptors, which can increase systemic vascular resistance and blood pressure. Clinical studies and case reports have associated its use with cardiovascular stimulant effects, including hypertensive urgency and increased heart rate, particularly when combined with caffeine.

Brand names
Xenadrine EFX
Other names
Xenadrine
02

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on Xenadrine EFX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xenadrine EFX.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call